How to appeal a CareFirst BCBS glp-1 weight-loss drugs denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for glp-1 weight-loss drugs

Cited policy: MP - Weight Loss Pharmacotherapy

BMI >=30, OR BMI >=27 with comorbidity. Comprehensive weight loss program participation. Continued benefit requires >=5% loss at 12 weeks.

How CareFirst BCBS denies glp-1 weight-loss drugs — and how to counter it

Where CareFirst BCBS pushes back: 1) BMI documentation outdated (>6 months); 2) No supervised weight loss program; 3) 12-week benefit review failed (<5% loss); 4) State-specific plans (TX, FL, AZ) more restrictive.

Counter-arguments that hold up: Request fresh BMI at appeal. Supervised program: include any structured program incl. virtual (Noom, WW digital). 12-week review failure: argue 24-week review citing STEP-1 mean loss at week 68 of 14.9%. State-specific: cite state insurance commissioner precedents.

What CareFirst BCBS typically denies for glp-1 weight-loss drugs

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For glp-1 weight-loss drugs, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the glp-1 weight-loss drugs treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Wegovy
• Zepbound
• Mounjaro
• Ozempic
• Saxenda
• PHENTERMINE AND TOPIRAMATE

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.